The Patent Finder

Fedora Pharmaceuticals Inc.

12 patents currently held · Updated Nov 15, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Nov 2032
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Apr 10, 2027
    The maintenance fee for Lactivicin Compounds, Their Preparation and Use as Antibacterial Agents (US 11,780,832) comes due Apr 10, 2027. Unpaid by Oct 12, 2027, it lapses early.
  • 1 fee due Jul 28, 2027
    The maintenance fee for Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors (US 10,544,146) comes due Jul 28, 2027. Unpaid by Jan 28, 2028, it lapses early.
  • 1 fee due Sep 10, 2027
    The maintenance fee for Pharmaceutical Forms of Diazabicyclooctane Derivatives and Manufacturing Method Thereof (US 10,584,123) comes due Sep 10, 2027. Unpaid by Mar 10, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 8,796,257Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,877,743Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,393,239Bicyclic compounds and their use as antibacterial agents and betalactamase inhibitors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,505,761Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,030,019Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,544,146Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,584,123Pharmaceutical Forms of Diazabicyclooctane Derivatives and Manufacturing Method Thereof
In force
 · High confidence
In forceHigh confidence
US 10,682,413Pharmaceutical Forms of Diazabicyclooctane Derivatives and Process for Producing the Same
In force
 · High confidence
In forceHigh confidence
US 10,759,800Crystalline Forms of Diazabicyclooctane Derivatives and Production Process Thereof
In force
 · High confidence
In forceHigh confidence
US 11,780,832Lactivicin Compounds, Their Preparation and Use as Antibacterial Agents
In force
 · High confidence
In forceHigh confidence
10 of 12 patents shown.
Pro members see all 12.
Pro members: see all 12 patents

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

Every application published under this name has become a patent.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited